bovin
respiratori
syncyti
viru
brsv
bovin
coronaviru
bcv
respons
respiratori
diseas
diarrhea
cattl
worldwid
norwegian
control
program
infect
base
herdlevel
diagnosi
use
new
multiplex
immunoassay
object
studi
estim
sensit
specif
across
differ
cutoff
valu
mvdenferplex
bcvbrsv
multiplex
compar
commerci
avail
elisa
svanovir
bcvab
svanovir
brsvab
respect
analyz
bulk
tank
milk
sampl
herd
lowand
herd
highpreval
area
none
test
consid
perfect
estim
test
characterist
perform
use
bayesian
latent
class
model
manufactur
recommend
cutoff
valu
median
sensit
brsv
multiplex
brsv
elisa
posterior
credibl
interv
pci
pci
respect
median
specif
brsv
multiplex
pci
pci
brsv
elisa
howev
increas
cutoff
brsv
elisa
increas
specif
without
compromis
sensit
bcv
multiplex
found
use
one
three
antigen
includ
test
specif
increas
without
concurr
loss
sensit
recommend
cutoff
result
sensit
pci
specif
pci
multiplex
sensit
pci
specif
pci
bcv
elisa
toftak
prevent
veterinari
medicin
bovin
coronaviru
bcv
bovin
respiratori
syncyti
viru
brsv
commonli
occur
agent
among
cattl
worldwid
valarch
taylor
boileau
kapil
endem
preval
also
norwegian
dairi
herd
gulliksen
et
al
klem
et
al
bcv
caus
respiratori
diseas
calf
diarrhea
winter
dysenteri
contagi
diarrhea
adult
cattl
boileau
kapil
brsv
caus
respiratori
diseas
mostli
young
anim
affect
anim
age
common
caus
respiratori
outbreak
norway
larsen
klem
et
al
consequ
infect
herd
health
problem
reduc
anim
welfar
increas
use
antibiot
due
secondari
bacteri
infect
larsen
valarch
taylor
boileau
kapil
therapi
cost
reduc
product
entail
consider
financi
loss
farmer
contribut
present
focu
nordic
countri
limit
spread
virus
cattl
popul
nation
control
program
brsv
bcv
infect
launch
norway
joint
initi
produc
organ
prompt
need
easi
costeffect
way
screen
dairi
herd
herd
level
diagnosi
brsv
bcv
initi
screen
control
program
conduct
use
bulk
tank
milk
sampl
btm
alreadi
commerci
avail
indirect
enzymelink
immunosorb
assay
elisa
wide
use
routin
diagnost
research
nordic
countri
svanovir
brsvab
svanovir
bcvab
et
al
klem
et
al
toftak
et
al
howev
order
optim
costeffect
control
program
develop
new
multiplex
antibodi
elisa
initi
mvdenferplex
bcvbrsv
multiplex
new
test
allow
screen
virus
use
singl
test
perform
diagnost
test
character
test
sensit
se
specif
sp
se
proport
true
posit
correctli
classifi
posit
test
sp
proport
true
neg
subject
correctli
classifi
neg
true
antibodi
statu
test
subject
determin
two
way
use
perfect
refer
test
base
popul
known
statu
howev
perfect
refer
test
often
term
gold
standard
rare
avail
endem
diseas
case
brsv
bcv
norway
refer
popul
complet
certainti
regard
diseas
diseas
freedom
exist
consequ
underli
true
infect
statu
test
subject
remain
unknown
test
valid
studi
erron
assum
perfect
refer
test
common
even
though
shown
introduc
bia
estim
accuraci
paramet
valenstein
lijmer
et
al
latent
class
analysi
lca
allow
estim
test
paramet
popul
underli
true
infect
statu
determin
hui
walter
lca
true
infect
statu
treat
exist
unknown
latent
variabl
test
accuraci
preval
parameter
accord
latent
variabl
brsvbcv
multiplex
new
test
need
valid
test
characterist
differ
test
use
herd
test
compar
use
individu
sampl
christensen
gardner
valid
relev
applic
therefor
import
btm
test
key
compon
norwegian
brsv
bcv
controlprogram
therefor
interest
estim
test
accuraci
differ
cutoff
valu
applic
aim
studi
estim
test
sensit
specif
newli
develop
mvdenferplex
bcvbrsv
multiplex
across
differ
cutoff
valu
detect
antibodi
btm
bcv
part
multiplex
compar
commerci
avail
svanovir
bcvab
brsv
part
multiplex
compar
svanovir
brsvab
neither
test
could
consid
perfect
evalu
done
use
lca
crosssect
sampl
design
use
present
studi
herd
elig
inclus
deliv
milk
largest
dairi
compani
norway
tine
sa
provid
btm
sampl
studi
period
march
herd
two
counti
expect
differ
true
preval
tp
select
order
meet
model
assumpt
describ
lca
section
use
random
number
gener
sampl
randomli
chosen
herd
oppland
pop
herd
sogn
og
fjordan
pop
counti
sogn
og
fjordan
locat
western
norway
assum
rel
low
preval
base
result
previou
studi
toftak
et
al
oppland
counti
locat
eastern
norway
thought
higher
preval
base
known
pattern
anim
movement
histori
previou
outbreak
diseas
toftak
et
al
btm
sampl
collect
nearli
norwegian
dairi
herd
deliv
milk
largest
dairi
cooper
tine
sa
march
sampl
collect
part
nation
control
program
brsv
bcv
milk
truck
driver
collect
sampl
ordinari
milk
shipment
use
standard
procedur
btm
sampl
milk
store
receiv
laboratori
tine
mastiti
laboratori
mold
norway
sampl
frozen
ship
overnight
enfer
laboratori
ireland
enfer
scientif
naa
ireland
sampl
kept
frozen
time
laboratori
analysi
svanovir
brsvab
hereaft
design
brsv
elisa
svanovir
bcvab
hereaft
design
bcv
elisa
use
sampl
follow
manufactur
instruct
optic
densiti
od
read
nm
correct
subtract
od
neg
control
antigen
percent
posit
ppvalu
calcul
correct
odposit
control
correct
od
accord
test
manual
recommend
cutoff
valu
sampl
posit
pp
test
use
start
point
test
svanova
svanova
brsv
elisa
se
sp
provid
manufactur
respect
paramet
calcul
serum
sampl
paramet
specif
btm
sampl
report
elvand
et
al
bcv
elisa
test
paramet
provid
manufactur
se
sp
brsv
calcul
base
serum
sampl
aleniu
et
al
sampl
analyz
use
mvdenferplex
bcvbrsv
multiplex
hereaft
refer
brsvbcv
multiplex
enfer
scientif
naa
ireland
panel
three
bcv
recombin
protein
bcv
ac
along
panel
two
recombin
protein
two
synthet
peptid
brsv
brsv
ad
use
antigen
briefli
antigen
deposit
multiplex
planar
array
individu
spot
well
well
microtit
plate
produc
array
antigen
sampl
dilut
sampl
dilut
buffer
mix
ad
well
incub
min
agit
wash
procedur
detect
antibodi
dilut
conjug
buffer
ad
plate
incub
min
agit
new
wash
final
chemiluminesc
substrat
ad
rel
light
unit
rlu
captur
exposur
immedi
use
quansi
bioscienc
imag
system
data
extract
use
quansi
q
view
softwar
v
antigen
combin
parallel
read
ie
test
consid
posit
rluvalu
least
one
antigen
appli
cutoff
laboratori
personnel
formal
blind
test
result
due
larg
volum
sampl
consid
blind
practic
purpos
multiplex
consist
sever
antigen
give
separ
respons
separ
cutoff
valu
need
antigen
calcul
proport
herd
posit
respons
individu
antigen
within
testposit
group
manufactur
recommend
cutoff
valu
defin
antigen
highest
proport
posit
respons
influenti
done
virus
later
choos
cutoff
valu
assess
chang
cutoff
influenti
antigen
viru
priorit
use
explor
approach
select
cutoff
valu
sever
differ
cutoff
valu
tri
influenti
antigen
fig
furthermor
evalu
test
perform
includ
singl
import
antigen
data
prepar
descript
analysi
perform
stata
stata
stata
corp
colleg
station
tx
present
studi
use
guidelin
report
diagnost
accuraci
studi
use
bayesian
lca
kostoula
et
al
target
condit
herd
one
anim
produc
bcvbrsvantibodi
contribut
bulk
tank
underli
latent
state
could
consid
previou
exposur
lead
antibodi
btm
use
lca
methodolog
diagnost
test
evalu
requir
set
assumpt
test
test
popul
fulfil
two
popul
differ
preval
includ
se
sp
diagnost
test
across
popul
test
condit
independ
cid
given
diseas
statu
hui
walter
ran
analys
assum
cid
test
howev
also
explor
consequ
relax
assumpt
explain
cidmodel
paramet
estim
sever
cutoff
valu
fig
model
fit
use
bayesian
lca
openbug
version
rev
softwar
use
noninform
prior
shape
uniform
distribut
interv
zero
one
model
use
beta
distribut
test
properti
subpopul
preval
analys
model
run
iter
use
burn
discard
converg
markov
chain
mont
carlo
mcmc
chain
assess
visual
inspect
histori
plot
timeseri
plot
gelmanrubin
diagnost
plot
use
three
sampl
chain
differ
initi
valu
suggest
toft
et
al
posterior
infer
done
calcul
median
posterior
credibl
interv
pci
se
sp
true
preval
model
descript
includ
appendix
correl
test
present
possibl
estim
two
test
scenario
without
includ
inform
prior
reliabl
prior
inform
test
perform
preval
present
studi
howev
consequ
relax
assumpt
condit
independ
given
diseas
statu
first
explor
vacek
examin
impact
condit
depend
assum
fix
proport
maximum
possibl
covari
test
follow
approach
explor
consequ
condit
depend
test
cutoff
valu
prefer
test
characterist
fig
altern
brsv
altern
bcv
see
appendix
detail
compar
result
condit
independ
model
model
allow
maximum
possibl
posit
covari
well
neg
covari
combin
differ
cutoff
valu
includ
antigen
cutoff
altern
present
fig
brsvand
bcv
multiplex
brsv
multiplex
brsva
antigen
respons
detect
major
posit
sampl
bcv
multiplex
antigen
detect
major
posit
sampl
bcva
count
test
outcom
test
present
tabl
brsv
bcv
test
respect
top
bcv
antigen
bottom
includ
bcvbrsv
multiplex
right
spider
plot
median
se
sp
differ
cutoff
altern
brsv
elisa
cutoff
fix
sampl
posit
pp
except
altern
sampl
posit
pp
use
bcv
elisa
cutoff
fix
sampl
posit
pp
test
paramet
estim
bayesian
lcm
analysi
count
pair
test
outcom
two
subpopul
brsvantibodi
test
brsv
multiplexbrsv
elisa
brsv
multiplex
vari
cutoff
valu
includ
antigen
use
shown
fig
brsv
elisa
cutoff
fix
sampl
posit
pp
except
altern
sampl
posit
pp
use
latent
class
analysi
brsv
estim
median
se
sp
true
preval
two
subpopul
brsvmultiplex
brsv
elisa
appli
differ
cutoff
valu
present
tabl
start
point
recommend
cutoff
valu
test
manufactur
appli
altern
fig
result
median
se
sp
brsv
multiplex
se
sp
elisa
sp
elisa
increas
se
cutoff
sampl
posit
pp
use
multiplex
increas
cutoff
valu
brsva
antigen
gener
result
lower
se
higher
sp
estim
could
expect
discard
antigen
except
brsva
result
increas
specif
howev
cost
significantli
reduc
sensit
seen
compar
cutoff
altern
tabl
point
estim
median
true
brsv
antibodi
preval
rang
pop
pop
result
cocmodel
fix
covari
show
allow
covari
alter
specif
estim
elisa
multiplex
chang
small
covari
less
maximum
possibl
covari
se
estim
notic
affect
allow
covari
result
sensit
analysi
present
tabl
estim
test
paramet
true
preval
two
subpopul
across
differ
cutoff
valu
bcv
multiplex
bcv
elisa
present
tabl
appli
cutoff
valu
current
recommend
test
manufactur
altern
fig
similar
observ
brsv
increas
cutoff
import
antigen
bcva
result
lower
se
higher
sp
bcv
multiplex
use
bcva
sole
antigen
cutoff
altern
tabl
median
sp
increas
median
se
remain
unchang
point
estim
median
true
bcv
antibodi
preval
rang
pop
pop
result
sensit
analysi
ie
allow
covari
test
show
neglig
effect
estim
testparamet
less
chang
paramet
covari
maximum
possibl
result
shown
estim
sensit
specif
new
multiplex
two
commerci
elisa
detect
brsv
bcv
antibodi
btm
use
lca
first
studi
evalu
mvdenferplex
brsvbcv
multiplex
present
studi
also
first
present
test
paramet
svanovir
brsvab
svanovir
bcvab
btm
brsv
multiplex
show
somewhat
lower
se
much
higher
sp
brsv
elisa
recommend
cutoff
valu
howev
increas
cutoff
brsv
elisa
sampl
posit
pp
result
larg
increas
sp
without
notabl
decreas
se
shown
tabl
result
therefor
suggest
higher
cutoff
recommend
manufactur
might
appropri
use
svanovir
brsvab
btm
bcv
specif
multiplex
notabl
lower
bcv
elisa
recommend
cutoff
use
three
antigen
howev
use
bcva
antigen
sp
improv
without
cost
reduc
se
test
perform
similar
bcv
elisa
impli
extra
antigen
ad
fals
posit
sampl
henc
reduc
sp
overal
two
test
studi
show
good
perform
detect
brsv
bcv
antibodi
possibl
benefit
choos
multiplex
therefor
lie
enabl
screen
agent
simultan
reduc
screen
cost
multiplex
evalu
present
studi
new
tabl
count
pair
test
outcom
two
subpopul
bcvantibodi
test
bcv
multiplexbcv
elisa
bcv
multiplex
vari
cutoff
valu
includ
antigen
use
shown
fig
bcv
elisa
cutoff
fix
sampl
posit
pp
tabl
test
paramet
estim
brsv
multiplex
brsv
elisa
sensit
specif
estim
true
preval
tp
two
subpopul
cutoff
altern
repres
differ
cutoff
altern
brsv
multiplex
present
tabl
brsv
elisa
cutoff
fix
sampl
posit
pp
altern
except
altern
brsv
elisa
cutoff
increas
sampl
posit
pp
test
relev
studi
could
compar
estim
howev
multiplex
technolog
shown
use
bovin
tuberculosi
cattl
goat
clegg
et
al
obrien
et
al
paramet
estim
provid
manufactur
svanovir
bcvab
base
data
studi
serum
sampl
analyz
use
elisa
viru
neutral
test
vnt
aleniu
et
al
estim
se
sp
calcul
use
vnt
gold
standard
svanovir
brsvab
se
sp
calcul
studi
compar
test
result
anoth
elisa
serum
sampl
thu
test
estim
rel
elisa
elvand
et
al
result
former
studi
compar
present
studi
due
differ
sampl
materi
serum
vs
btm
even
import
note
studi
assum
perfect
refer
test
estim
se
sp
index
test
never
exceed
gold
standard
thu
higher
se
brsv
bcv
elisa
found
studi
unexpect
explor
effect
differ
cutoff
valu
test
characterist
appli
rang
cutoff
valu
multiplex
antigen
whenev
cutoff
chang
could
entail
chang
definit
latent
condit
chang
number
true
posit
true
neg
herd
rel
littl
variat
se
sp
estim
brsvand
bcv
elisa
across
differ
cutoff
valu
explor
chang
estim
true
preval
minor
test
gener
agre
proport
posit
herd
indic
test
good
agreement
underli
target
condit
explor
approach
choos
cutoff
potenti
weak
current
studi
howev
differ
scenario
provid
exampl
expect
perform
differ
cutoff
repres
optim
diagnost
test
chosen
cutoff
tabl
result
sensit
analysi
brsv
median
estim
posterior
credibl
interv
pci
sensit
se
specif
sp
bulk
tank
milk
brsv
multiplex
brsv
elisa
manufactur
recommend
cutoff
altern
fig
condit
independ
cid
model
condit
depend
coc
model
covari
express
proport
maximum
possibl
valu
test
paramet
bcv
multiplex
bcv
elisa
sensit
specif
estim
true
preval
tp
two
subpopul
cutoff
altern
repres
differ
cutoff
altern
bcv
multiplex
present
tabl
bcv
elisa
cutoff
fix
sampl
posit
pp
altern
like
affect
number
antibodi
produc
anim
need
posit
btm
result
posit
correl
withinherd
preval
odvalu
shown
diseas
musken
et
al
nekouei
et
al
typic
norwegian
dairi
herd
small
mean
herd
size
anon
compar
develop
countri
might
influenc
generaliz
result
larger
herd
antibodi
might
dilut
bulk
tank
henc
caus
test
se
decreas
howev
larger
herd
might
also
posit
anim
care
evalu
model
assumpt
crucial
perform
lca
violat
assumpt
might
lead
bias
result
assumpt
differ
preval
popul
central
lca
model
toft
et
al
show
precis
accuraci
paramet
improv
increas
differ
preval
among
popul
studi
present
studi
differ
preval
two
subpopul
rel
larg
addit
suffici
sampl
size
lead
narrow
posterior
credibl
interv
se
sp
estim
second
assumpt
test
characterist
constant
popul
norwegian
dairi
herd
rel
homogen
two
subpopul
studi
like
similar
term
breed
product
system
potenti
sourc
variat
test
characterist
subpopul
could
antigen
divers
within
norwegian
dairi
herd
find
antigen
divers
bcv
summar
saif
conclud
singl
serotyp
known
base
viru
crossneutr
test
high
level
cross
protect
shown
respiratori
enter
isol
brsv
norwegian
studi
found
current
norwegian
strain
brsv
belong
subgroup
north
european
isol
indic
withincountri
divers
like
limit
klem
et
al
addit
crossreact
like
common
even
shown
isol
differ
speci
oberst
et
al
even
though
seem
unlik
spatial
antigen
divers
play
import
role
sourc
bia
exclud
complet
certainti
final
assumpt
met
condit
independ
test
given
diseas
statu
sever
paper
argu
test
similar
biolog
basi
assumpt
like
met
branscum
et
al
condit
independ
test
mean
probabl
posit
neg
result
one
test
regardless
result
test
given
true
diseas
state
et
al
toft
et
al
condit
depend
would
term
fals
posit
mean
second
test
like
pick
herd
fals
posit
alreadi
test
fals
posit
first
test
instanc
due
crossreact
agent
estim
covari
test
se
sp
two
extra
degre
freedom
need
two
test
two
popul
scenario
result
unidentifi
model
ie
possibl
estim
covari
without
includ
prior
inform
reliabl
prior
inform
could
obtain
test
paramet
preval
present
studi
anoth
approach
potenti
allow
estim
covari
would
includ
third
test
either
anoth
antibodi
test
test
detect
viru
eg
qpcr
first
option
would
necessarili
allow
estim
covari
unless
third
test
underli
properti
substanti
differ
two
test
ad
antigen
test
might
ensur
condit
independ
howev
would
chang
underli
diseas
statu
involv
serolog
respons
also
coher
shed
viru
explor
consequ
condit
depend
sensit
analysi
includ
fix
covari
proport
maximum
possibl
covari
test
bcv
estim
allow
covari
latent
class
model
neglig
effect
paramet
estim
test
se
bcv
multiplex
sp
bcv
elisa
close
one
small
effect
covari
expect
shown
mathemat
test
se
sp
condit
independ
whenev
one
test
se
sp
see
appendix
detail
also
situat
brsvse
se
elisa
close
howev
cocmodel
fix
covari
yield
chang
estim
specif
brsv
test
becam
notabl
covari
assum
larger
maximum
summari
effect
covari
small
except
brsvsp
high
valu
covari
import
note
sensit
analysi
give
indic
effect
covari
present
answer
whether
covari
exist
even
though
test
studi
antibodi
test
differ
way
design
first
elisa
use
crude
whole
viru
elisa
well
wherea
brsvbcv
multiplex
use
peptid
recombin
protein
second
test
use
differ
techniqu
detect
elisa
use
chromogen
substrat
result
base
read
optic
densiti
wherea
brsvbcv
multiplex
use
chemiluminesc
substrat
result
base
read
light
emiss
differ
make
violat
condit
independ
assumpt
less
like
conclus
brsvbcv
multiplex
brsvbcv
elisa
show
similar
perform
appli
btm
sampl
sp
bcv
multiplex
improv
use
bcva
antigen
low
sp
brsv
elisa
improv
increas
cutoff
use
test
btm
nt
ms
ls
declar
conflict
interest
gh
nw
founder
mv
diagnost
develop
multiplex
test
ao
b
also
develop
multiplex
test
enfer
employe
howev
neither
mv
diagnost
enfer
involv
dataanalysi
could
inappropri
influenc
work
se
sp
condit
covari
coc
among
infect
noninfect
test
subject
respect
presenc
coc
test
given
diseas
statu
impli
se
andor
sp
latent
class
model
assum
ith
subpopul
count
differ
combin
test
result
eg
pospo
po
neg
etc
two
test
follow
multinomi
distribut
se
j
sp
j
p
multinomin
prob
n
j
number
subpopul
j
index
test
prob
vector
probabl
observ
individu
combin
test
result
ith
subpopul
true
preval
tp
model
cid
test
obtain
let
se
sp
express
express
prob
possibl
deriv
upper
lower
limit
se
sp
sinc
element
probabl
vector
must
zero
one
thu
let
se
sp
either
test
equal
equat
follow
associ
condit
covari
limit
zero
thu
impli
condit
independ
respect
se
andor
sp
two
test
given
diseas
statu
frequentist
statist
confid
interv
includ
zero
evid
statist
signific
similar
approach
adopt
bayesian
set
posterior
credibl
interv
condit
depend
without
zero
indic
condit
depend
includ
model
covari
express
either
se
sp
proport
covari
rel
maximum
valu
